ArticleFrontiers in neurology

Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis.

Khalid Bin Aziz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.